Journal issues > Issue 1, February 2022 > Highlights in thrombosis and Haemostasis

Highlights in thrombosis and Haemostasis

SUMMARY

New therapeutic developments in the field of haemophilia were highlighted at the ASH 2021 congress. These included the results of inhibition of antithrombin production via fitusiran for the prevention of bleeding events in haemophilia A and B patients with or without inhibitors, the success of emicizumab, a bispecific antibody that mimics the action of FVIII, in patients with moderate or mild haemophilia A, and finally the promising results of FVIII fused to the Fc fragment of the immunoglobulins as an agent for FVIII tolerance induction in patients with inhibitors. In the field of antithrombotics, a meta-analysis confirms the place of direct oral anticoagulants in cancer patients with thrombosis. Xarelto has demonstrated its value in patients with visceral venous thrombosis and a large study does not support the thrombogenicity of mRNA-based COVID vaccines.

(BELG J HEMATOL 2022;13(1):37-42)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top